Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
C. H.Chen
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=1.414
------>paper_class3=2
------>paper_class2=1
------>vol=26
------>confirm_bywho=None
------>insert_bywho=enochlai49
------>Jurnal_Rank=81.8
------>authors4_c=
------>comm_author=
------>patent_EDate=None
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=None
------>page2=3716
------>medlineContent=
------>unit=000
------>insert_date=20090311
------>iam=7
------>update_date=None
------>author=???
------>change_event=1
------>ISSN=
------>authors_c=
------>score=500
------>journal_name=Anticancer research
------>paper_name=Post-operative concurrent chemoradiation therapy using oral Uracil-tegafur versus weekly intravenous Fluorouracil for locally advanced rectal cancer
------>confirm_date=None
------>tch_id=083041
------>pmid=17094389
------>page1=3709
------>fullAbstract=BACKGROUND: This prospective, nonrandomized study was conducted to compare the efficacy and toxicity of post-operative concurrent chemoradiation therapy (CCRT) using daily oral uracil-tegafur plus leucovorin (UFUR/LV) vs. weekly intravenous fluorouracil plus leucovorin (5-FU/LV) in patients with locally advanced rectal cancer. MATERIALS AND METHODS: From November 1996 through December 2004, 30 patients with stage II or III rectal cancer were enrolled. Either 5-FU (400 to 450 mg/m2) plus LV (80 to 100 mg/m2) weekly or oral UFUR (250 to 300 mg/m2/d) plus oral LV (30 to 45 mg/m2/d) were given during radiotherapy. Radiation (50.4 to 60.4 Gy) was delivered to the tumor bed in 28-33 fractions. RESULTS: The mean survival, 2-year overall survival and disease-free survival were 36 months vs. 30 months, 68% vs. 66% and 55% vs. 50%, (p > 0.05), in the UFUR/LV and 5-FU/LV groups, respectively. There were no treatment-related deaths or grade 4 toxicity in either group. Grade 3 dermatitis, gastrointestinal and hematologic toxicity were noted in the 5-FU/LV group. CONCLUSION: Because of a similar survival rate and lower toxicity, oral UFUR/LV is suggested as an alternative regimen to intravenous 5-FU/LV in post-operative CCRT of locally advanced rectal cancer.
------>tmu_sno=None
------>sno=21312
------>authors2=Y. J.Chen
------>authors3=K. H.Chang
------>authors4=H. H.Hsu
------>authors5=C. K.Liu
------>authors6=S. K.Hung, H. W.Chen, Y.L.LAi, T. C.Hsu
------>authors6_c=
------>authors=C. H.Chen
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2006
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z